{"schema_version":"secwatch.filing_event.v1","accession":"0001847367-25-000010","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.267912+00:00","generated_at":"2026-05-24T12:08:29.258569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025","bullets":["Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.","Cash, cash equivalents and marketable securities of $288.3M as of Dec 31, 2024.","All-stock merger with ACELYRIN; pro forma cash ~$737M; Alumis stockholders to own ~55% on diluted basis.","Phase 3 ESK-001 psoriasis topline data expected Q1 2026; Phase 2 MS trial for A-005 to start 2H 2025.","Appointed Jack Danilkowicz as CCO and Sara Klein as CLO to bolster late-stage capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001847367-25-000010","json":"https://secwatch.observer/filing/0001847367-25-000010.json","markdown":"https://secwatch.observer/filing/0001847367-25-000010.md","text":"https://secwatch.observer/filing/0001847367-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/0001847367-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:08:29.258569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}